1 / 10

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer. With permission from Hudis CA. N Engl J Med. 2007;357:39-51. ALTTO Formerly Known as APHRODITE. Inclusion Criteria • HER2+ breast cancer • ≥4 cycles anthracycline-based neoadjuvant chemotherapy • LVEF ≥50%.

iona
Download Presentation

Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trials of Adjuvant Trastuzumab in HER2+ Early-Stage Breast Cancer With permission from Hudis CA. N Engl J Med. 2007;357:39-51.

  2. ALTTO Formerly Known as APHRODITE Inclusion Criteria • HER2+ breast cancer • ≥4 cycles anthracycline-based neoadjuvant chemotherapy • LVEF ≥50% Trastuzumab x 1 year Lapatinib x 1 year Randomize Trastuzumab x 1 year + lapatinib x 1 year Trastuzumab x 12 weeks Break 6 weeks Lapatanib x 34 weeks Clinicaltrials.gov. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00490139?term=A.Accessed on: September 15, 2009. ALLTOTRIALS.COM—Trial Overview. Available at: http://www.alttotrials.com/patients.php#5. Accessed on: September 15, 2009.

  3. Refine Antibodies Targeting HER2+ Tumors Inhibit Dimerization Moderate Receptor Expression Inhibit Kinase Activity Potentiate Downstream Effects With permission from Burstein HJ. N Engl J Med. 2005;353:1652-1654.

  4. Mechanism of Cell Death from Inhibition of Polyadenosine Diphosphate-Ribose Polymerase 1 (PARP-1) With permission from Iglehart JD, et al. N Engl J Med. 2009;361:189-191.

  5. Radiologic Evidence of Tumor Response to Olaparib A Patient 20at Baseline Patient 20at 4 Months Patient 41at Baseline Patient 41at 4 Months With permission from Fong PC, et al. N Engl J Med. 2009;361:123-134.

  6. BevacizumabSummary of Breast Cancer Studies 1. Miller KD, et al. J Clin Oncol. 2005;23:792-799. 2. Miles D, et al. 44th ASCO; May 30-June 3, 2008. Abstract LBA1011. 3. Miller K, et al. N Engl J Med. 2007;357:2666-2676. 4. Robert NJ, et al. 45th ASCO; May 29-June 2, 2009. Abstract 1005.

  7. VEGF Signaling Pathway in Angiogenesis With permission from Kerbel RS. N Engl J Med. 2008;358:2039-2049.

  8. NSABP B-20 Outcomeby Recurrence Score Overall Low risk: <18 Intermediate risk: 18–30 High risk: >30 With permission from Paik S, et al. J Clin Oncol. 2006;24:3726-3734.

  9. Oncotype DX Breast Cancer Assay • Oncotype DX recurrence score tends to correlate with established breast cancer prognostic/predictive factors • Age • Tumor grade • HER2 • Quantitative ER/PR levels • Tumor size • The “poor man’s” Oncotype DX • TN stage, grade, ER, PR, HER2 Oncotype DX, Breast Cancer Assay. Available at: www.oncotypedx.com. Accessed on: September 14, 2009.

  10. Multigene Arrays and Prediction of Relapse-Free Survival in Breast Cancer With permission from Fan C, et al. N Engl J Med. 2006;355:560-569.

More Related